First-Ever Prostate Cancer Treatment Guidelines Translated For Patients
PHILADELPHIA (June 23, 1999) -- For the first time ever, men with prostate cancer have an invaluable new resource in their fight against the disease. Treatment guidelines written by the nation's top cancer specialists have been translated into easy-to-understand text so patients and their families have reliable and specific information to make timely and well-informed decisions about their treatment.
The guidelines are provided by the National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS). Fox Chase Cancer Center is a founding member of the NCCN, a nationwide network of leading cancer centers. Physicians look to the NCCN for guidance on the highest quality and most effective advice on cancer treatment. The NCCN's mission is to make state-of-the-art cancer care available nationwide, through treatment guidelines for physicians and for patients.
"Cancer specialists regard the NCCN treatment guidelines as the defining treatment standard," said Louis M. Weiner, M.D., chairman of medical oncology at Fox Chase Cancer Center. "The patient guidelines answer frequently asked questions men have after their initial diagnosis of prostate cancer, including stages of the disease, types of available treatments, possible side effects and information about clinical trials. Having this information allows patients to better understand their treatment options."
After studying research results on prostate cancer treatment, a panel of NCCN experts has agreed upon specific, up-to-date recommendations for treating men with this disease. These recommendations were formulated using scientific evidence and currently accepted approaches to treatment. Every year the panel will update their recommendations, if advances in medical science warrant it.
To obtain copies of the patient versions of the guidelines for breast and prostate cancer treatment, contact the National Comprehensive Cancer Network at 1-888-909-NCCN or American Cancer Society at 1-800-ACS-2345. You may also visit the Fox Chase Cancer Center web site at www.fccc.edu.
Founded in 1995, the National Comprehensive Cancer Network, was created with one goal in mind: to fight cancer more effectively. A total of 17 prestigious institutions, representing the finest in cancer care across the United States, are part of the Network.
The American Cancer Society is the nationwide, community-based voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer, saving lives and diminishing suffering from cancer through research, education, advocacy and service.
Fox Chase Cancer Center is one of 35 National Cancer Institute-designated comprehensive cancer centers in the nation. The Center's activities include basic and clinical research; prevention, detection and treatment of cancer; and community outreach programs.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.